Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 17/20 | 0.56 |
| ▸ | BCL2 | P10415 | 15/20 | 0.56 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.49 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943266 | 0.87 | BCL2L1 (0.59) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL2943265 | 0.85 | BCL2L1 (0.63) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL2953530 | 0.84 | BCL2L1 (0.61) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL4478837 | 0.83 | BCL2L1 (0.55) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL6794026 | 0.82 | SMN1; SMN2 (0.48) | MCL1 | |
| SCHEMBL2943747 | 0.82 | BCL2L1 (0.66) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL2952249 | 0.80 | BCL2L1 (0.62) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL4461569 | 0.76 | BCL2L1 (0.74) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL2944006 | 0.75 | BCL2L1 (0.72) | BCL2L1BCL2BADAURKAPLK1 | |
| SCHEMBL2944693 | 0.74 | BCL2L1 (0.59) | BCL2L1BCL2BADAURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885BAD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.